Perspective Therapeutics (CATX) vs ClearPoint Neuro (CLPT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Perspective Therapeutics (CATX) has outperformed ClearPoint Neuro (CLPT) over the past year, losing 29.1% versus a loss of 59.6%. Over five years, CLPT leads with a -40.6% price change compared with -60.3% for CATX. ClearPoint Neuro is the larger company by market cap ($313.3 million vs $276.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CATX | CLPT |
|---|---|---|
| Share price | $2.43 | $10.27 |
| Market cap | $276.82M | $313.28M |
| 1-day change | -1.42% | -3.66% |
| YTD return | -10.55% | -22.08% |
| 1-year return | -29.11% | -59.61% |
| 5-year return | -60.32% | -40.65% |
| EPS (TTM) | $-1.33 | $-1.18 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.16 | $30.10 |
| 52-week low | $1.96 | $8.27 |
| Distance from 52-week high | -60.63% | -65.88% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +406.80% | +128.82% |
| Average volume | 1.67M | 637.17K |
| Shares outstanding | 114.15M | 30.50M |
| Employees | 163 | 160 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CATX has outperformed CLPT by 30.5 percentage points over the past year.
About Perspective Therapeutics
CATX stock →Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha.
Health Care · Biotechnology: Pharmaceutical Preparations · 163 employees
About ClearPoint Neuro
CLPT stock →ClearPoint Neuro, Inc., a commercial-stage medical device company, focuses on the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain in the United States. The company offers ClearPoint systems, such as ClearPoint hardware, which includes head fixation frame, computer workstation, and in-room monitor; and ClearPoint disposables, which consist of SmartFrame trajectory device, a hand controller and related accessories, and its SmartFlow Neuro cannula.
Health Care · Medical/Dental Instruments · 160 employees
CATX vs CLPT FAQ
Which is bigger, Perspective Therapeutics or ClearPoint Neuro?
ClearPoint Neuro (CLPT) is larger, with a market capitalization of $313.28M compared with $276.82M for Perspective Therapeutics (CATX).
Which stock has performed better over the past year, CATX or CLPT?
CATX returned -29.11% over the past 12 months, compared with -59.61% for CLPT (price return, excluding dividends). Past performance does not predict future results.
Are Perspective Therapeutics and ClearPoint Neuro in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Perspective Therapeutics and Medical/Dental Instruments for ClearPoint Neuro.